Pancreatic Cancer Research

ResearcherUniversity of LiverpoolActive in the last 2 years

Paula Ghaneh

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1950-5645; OpenAlex author ID A5020254111, A5108296476. Sources: OpenAlex.

Their work

Papers
49 (first author 4, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
225
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: none · 2014: 2 papers · 2015: 2 papers · 2016: 3 papers · 2017: 4 papers · 2018: 5 papers · 2019: 5 papers · 2020: 2 papers · 2021: 4 papers · 2022: 6 papers · 2023: 2 papers · 2024: 5 papers · 2025: 4 papers · 2026: 3 papers

Papers 49

  1. Risk-stratified surveillance for individuals in the UK at high risk of developing pancreatic cancer: Outcomes from the European Registry of Hereditary Pancreat… Co-author DOI 10.1016/j.ejca.2026.116592↗
  2. Real-world outcomes following adjuvant chemotherapy for resected pancreatic cancer in a centralised oncology service. Co-author DOI 10.1038/s41416-026-03341-0↗
  3. NQO1 as a predictor of response to adjuvant GemCap treatment for pancreatic cancer. Co-author DOI 10.1093/jnci/djaf345↗
  4. GATA6 immunohistochemistry and prognosis after surgical resection of pancreatic adenocarcinoma: results from the ESPAC-4 trial. Co-author DOI 10.1016/j.esmogo.2025.100138↗
  5. Impact of social deprivation upon the preoperative pathway and early surgical outcomes after pancreatoduodenectomy for PDAC and non-PDAC periampullary cancer i… Co-author DOI 10.1016/j.hpb.2025.07.007↗
  6. Neoadjuvant treatment versus upfront surgery in borderline resectable and resectable pancreatic ductal adenocarcinoma: meta-analysis. Last author DOI 10.1093/bjsopen/zrae172↗
  7. Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial. Co-author DOI 10.1200/jco.24.01118↗
  8. Metastatic pancreatic cancer: a new standardised dose-reduction regimen? Co-author DOI 10.1016/s2468-1253(24)00227-9↗
  9. Macrophage-fibroblast JAK/STAT dependent crosstalk promotes liver metastatic outgrowth in pancreatic cancer. Co-author DOI 10.1038/s41467-024-47949-3↗
  10. Efferocytosis reprograms the tumor microenvironment to promote pancreatic cancer liver metastasis. Co-author DOI 10.1038/s43018-024-00731-2↗
  11. Author Correction: Efferocytosis reprograms the tumor microenvironment to promote pancreatic cancer liver metastasis. Co-author DOI 10.1038/s43018-024-00751-y↗
  12. Mesothelin Secretion by Pancreatic Cancer Cells Co-opts Macrophages and Promotes Metastasis. Co-author DOI 10.1158/0008-5472.can-23-1542↗
  13. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable… Co-author DOI 10.1016/s2468-1253(22)00348-x↗
  14. GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/gutjnl-2021-325803↗
  15. Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB): A Syst… Co-author DOI 10.1001/jamaoncol.2022.0168↗
  16. Concordance of human equilibrative nucleoside transporter-1 expressions between murine (10D7G2) and rabbit (SP120) antibodies and association with clinical out… Co-author DOI 10.1002/cnr2.1507↗
  17. Blood levels of adiponectin and IL-1Ra distinguish type 3c from type 2 diabetes: Implications for earlier pancreatic cancer detection in new-onset diabetes. Co-author DOI 10.1016/j.ebiom.2021.103802↗
  18. Treatment of unresectable locally advanced pancreatic cancer with percutaneous irreversible electroporation (IRE) following initial systemic chemotherapy (LAP-… Co-author DOI 10.1136/bmjopen-2021-050166↗
  19. United Kingdom Early Detection Initiative (UK-EDI): protocol for establishing a national multicentre cohort of individuals with new-onset diabetes for early de… Co-author DOI 10.1136/bmjopen-2022-068010↗
  20. Chemotherapy-induced infiltration of neutrophils promotes pancreatic cancer metastasis via Gas6/AXL signalling axis. Co-author DOI 10.1136/gutjnl-2021-325272↗
  21. Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic". Co-author DOI 10.1038/s41416-020-01133-8↗
  22. Optimising treatment pathways for borderline and locally advanced pancreatic cancer: an adaptive personalised approach. First author DOI 10.1038/s41416-021-01416-8↗
  23. Multimodality standard of care treatment of resectable and borderline resectable pancreatic cancer. First author DOI 10.21037/hbsn-21-131↗
  24. hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. Co-author DOI 10.3390/cancers13225758↗
  25. Prognostic value of 18FDG PET/CT volumetric parameters in the survival prediction of patients with pancreatic cancer. Last author DOI 10.1016/j.ejso.2020.02.002↗
  26. Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. Co-author DOI 10.1038/s41416-020-0980-x↗
  27. Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial. Co-author DOI 10.1001/jamasurg.2019.3337↗
  28. Differentiation of Autoimmune Pancreatitis from Pancreatic Cancer Remains Challenging. Co-author DOI 10.1007/s00268-019-04928-w↗
  29. Identification of Cystic Lesions by Secondary Screening of Familial Pancreatic Cancer (FPC) Kindreds Is Not Associated with the Stratified Risk of Cancer. Co-author DOI 10.1038/s41395-018-0395-y↗
  30. The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000002557↗
  31. Response to Comment on "The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal… First author DOI 10.1097/sla.0000000000003371↗
  32. Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. Co-author DOI 10.1038/s41416-018-0004-2↗
  33. Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pa… Co-author DOI 10.1038/s41416-018-0005-1↗
  34. Pancreatic Cancer and FOLFIRINOX: Should We Resect All Responders? Co-author DOI 10.1097/sla.0000000000002026↗
  35. Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer: A Post-hoc Analysis From the International Phase III ESPAC-3 Clinical Tria… Co-author DOI 10.1097/sla.0000000000002088↗
  36. PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-gluco… Co-author DOI 10.3310/hta22070↗
  37. Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamaoncol.2016.3916↗
  38. Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based… Co-author DOI 10.1002/bjs.10482↗
  39. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-lab… Co-author DOI 10.1016/s0140-6736(16)32409-6↗
  40. GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2015-311256↗
  41. Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/bjc.2015.468↗
  42. The impact of diabetes mellitus on survival following resection and adjuvant chemotherapy for pancreatic cancer. Co-author DOI 10.1038/bjc.2016.277↗
  43. Association of genetic polymorphisms with survival of pancreatic ductal adenocarcinoma patients. Co-author DOI 10.1093/carcin/bgw080↗
  44. Incidence of post-ERCP pancreatitis from direct pancreatic juice collection in hereditary pancreatitis and familial pancreatic cancer before and after the intr… Co-author DOI 10.1097/mpa.0000000000000246↗
  45. Biomarkers for early diagnosis of pancreatic cancer. Co-author DOI 10.1586/17474124.2015.965145↗
  46. Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to… Co-author DOI 10.1016/j.ejca.2014.07.011↗
  47. Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. First author DOI 10.1093/jnci/djt347↗
  48. Adjuvant therapy for pancreatic cancer. Co-author DOI 10.1007/978-3-642-31629-6_5↗
  49. Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer. Last author DOI 10.1038/bjc.2011.110↗

Closest collaborators

The 25 strongest of 225 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Christopher Michael Halloran · 31 shared papers, 2014–2026 · strength 3.67
  2. John P. Neoptolemos · 31 shared papers, 2011–2026 · strength 2.86
  3. Daniel H. Palmer · 23 shared papers, 2014–2025 · strength 2.21
  4. William Greenhalf · 20 shared papers, 2014–2026 · strength 1.89
  5. Eithne Costello · 16 shared papers, 2014–2026 · strength 1.48
  6. Thilo Hackert · 10 shared papers, 2016–2026 · strength 1.29
  7. Daniel H. Palmer · 4 shared papers, 2024–2026 · strength 1.19
  8. Markus Wolfgang Büchler · 14 shared papers, 2014–2025 · strength 1.11
  9. Michael C. Schmid · 6 shared papers, 2022–2025 · strength 1.10
  10. Ainhoa Mielgo · 6 shared papers, 2022–2025 · strength 1.10
  11. Juan W. Valle · 11 shared papers, 2014–2025 · strength 0.88
  12. Gaia Bellomo · 5 shared papers, 2022–2024 · strength 0.84
  13. Robert Peter Jones · 6 shared papers, 2017–2024 · strength 0.79
  14. Valeria Quaranta · 4 shared papers, 2022–2024 · strength 0.64
  15. Yuliana Astuti · 4 shared papers, 2022–2024 · strength 0.64
  16. Meirion Raymant · 4 shared papers, 2022–2024 · strength 0.64
  17. Jennifer P. Morton · 4 shared papers, 2022–2024 · strength 0.64
  18. Bengt L. G. Glimelius · 9 shared papers, 2014–2025 · strength 0.60
  19. David Cunningham · 6 shared papers, 2017–2025 · strength 0.54
  20. Olusola Olusesan Faluyi · 4 shared papers, 2017–2026 · strength 0.53
  21. Christoph Springfeld · 3 shared papers, 2023–2026 · strength 0.50
  22. Lucy S. Oldfield · 3 shared papers, 2022–2026 · strength 0.48
  23. Stephen P. Pereira · 4 shared papers, 2018–2026 · strength 0.48
  24. Ganesh Radhakrishna · 3 shared papers, 2020–2021 · strength 0.47
  25. Markus M. Lerch · 7 shared papers, 2016–2021 · strength 0.45

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.